vs
Arbutus Biopharma Corp（ABUS）与太平洋生物科学（ASMB）财务数据对比。点击上方公司名可切换其他公司
太平洋生物科学的季度营收约是Arbutus Biopharma Corp的1.0倍（$10.8M vs $10.7M），Arbutus Biopharma Corp净利率更高（23.5% vs -85.2%，领先108.7%），Arbutus Biopharma Corp同比增速更快（522.2% vs 57.6%）
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
ABUS vs ASMB — 直观对比
营收规模更大
ASMB
是对方的1.0倍
$10.7M
营收增速更快
ABUS
高出464.6%
57.6%
净利率更高
ABUS
高出108.7%
-85.2%
损益表 — Q2 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.7M | $10.8M |
| 净利润 | $2.5M | $-9.2M |
| 毛利率 | — | — |
| 营业利润率 | 13.9% | -100.9% |
| 净利率 | 23.5% | -85.2% |
| 营收同比 | 522.2% | 57.6% |
| 净利润同比 | 112.7% | 4.3% |
| 每股收益（稀释后） | $0.01 | $-0.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABUSASMB
| Q3 25 | — | $10.8M | ||
| Q2 25 | $10.7M | $9.6M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $7.4M | ||
| Q3 24 | — | $6.8M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $5.8M | ||
| Q4 23 | $2.1M | — |
净利润ABUSASMB
| Q3 25 | — | $-9.2M | ||
| Q2 25 | $2.5M | $-10.2M | ||
| Q1 25 | — | $-8.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-9.6M | ||
| Q2 24 | — | $-11.2M | ||
| Q1 24 | — | $-9.1M | ||
| Q4 23 | — | — |
营业利润率ABUSASMB
| Q3 25 | — | -100.9% | ||
| Q2 25 | 13.9% | -115.2% | ||
| Q1 25 | — | -105.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -160.1% | ||
| Q2 24 | — | -143.0% | ||
| Q1 24 | — | -185.5% | ||
| Q4 23 | -967.2% | — |
净利率ABUSASMB
| Q3 25 | — | -85.2% | ||
| Q2 25 | 23.5% | -105.9% | ||
| Q1 25 | — | -93.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.4% | ||
| Q2 24 | — | -130.7% | ||
| Q1 24 | — | -156.9% | ||
| Q4 23 | — | — |
每股收益（稀释后）ABUSASMB
| Q3 25 | — | $-0.72 | ||
| Q2 25 | $0.01 | $-1.33 | ||
| Q1 25 | — | $-1.17 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.51 | ||
| Q2 24 | — | $-1.98 | ||
| Q1 24 | — | $-1.66 | ||
| Q4 23 | $-0.12 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $22.5M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $83.0M | $182.7M |
| 总资产 | $103.3M | $240.0M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ABUSASMB
| Q3 25 | — | $22.5M | ||
| Q2 25 | $37.4M | $24.0M | ||
| Q1 25 | — | $23.4M | ||
| Q4 24 | — | $38.3M | ||
| Q3 24 | — | $28.5M | ||
| Q2 24 | — | $19.2M | ||
| Q1 24 | — | $18.7M | ||
| Q4 23 | $126.0M | — |
总债务ABUSASMB
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $0 | — |
股东权益ABUSASMB
| Q3 25 | — | $182.7M | ||
| Q2 25 | $83.0M | $18.1M | ||
| Q1 25 | — | $27.1M | ||
| Q4 24 | — | $33.4M | ||
| Q3 24 | — | $26.0M | ||
| Q2 24 | — | $34.7M | ||
| Q1 24 | — | $32.6M | ||
| Q4 23 | $106.0M | — |
总资产ABUSASMB
| Q3 25 | — | $240.0M | ||
| Q2 25 | $103.3M | $80.8M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | — | $119.2M | ||
| Q3 24 | — | $100.3M | ||
| Q2 24 | — | $115.3M | ||
| Q1 24 | — | $119.9M | ||
| Q4 23 | $144.4M | — |
负债/权益比ABUSASMB
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.7M | $-15.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-15.2M |
| 自由现金流率自由现金流/营收 | — | -140.7% |
| 资本支出强度资本支出/营收 | 0.0% | 0.4% |
| 现金转化率经营现金流/净利润 | -6.24× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABUSASMB
| Q3 25 | — | $-15.1M | ||
| Q2 25 | $-15.7M | $-16.8M | ||
| Q1 25 | — | $-23.4M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | — | $-15.2M | ||
| Q2 24 | — | $-17.1M | ||
| Q1 24 | — | $-18.4M | ||
| Q4 23 | $-17.3M | — |
自由现金流ABUSASMB
| Q3 25 | — | $-15.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-17.1M | ||
| Q1 24 | — | $-18.4M | ||
| Q4 23 | — | — |
自由现金流率ABUSASMB
| Q3 25 | — | -140.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -695.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -200.6% | ||
| Q1 24 | — | -317.7% | ||
| Q4 23 | — | — |
资本支出强度ABUSASMB
| Q3 25 | — | 0.4% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.2% | ||
| Q4 23 | 0.0% | — |
现金转化率ABUSASMB
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
